Novo Nordisk's Obesity Pill Approval Drives Stock Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 24 Dec 25
Novo Nordisk A/S shares rose by 3.10%, reaching a 20-day high, following the FDA's approval of its first GLP-1 oral obesity pill.
This surge is attributed to the FDA's approval of Novo Nordisk's first GLP-1 oral obesity pill, which is expected to significantly expand market access and provide a competitive edge over Eli Lilly. The approval is seen as a major milestone in the obesity treatment market, likely attracting more consumers and enhancing Novo Nordisk's market share.
The approval not only positions Novo Nordisk favorably against competitors but also opens up a substantial market potential, with analysts projecting the GLP-1 market could reach approximately $100 billion by 2030, further driving revenue growth for the company.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 62.890
Low
42.00
Averages
54.67
High
70.00
Current: 62.890
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
